
President Donald Trump on Thursday unveiled what the White House calls the “Great Healthcare Plan,” an affordability-first package that he says would lower prescription drug prices and insurance premiums, while increasing transparency in the health system.
The proposal leans heavily on pressure for lower prices and new disclosure requirements, but it is not yet clear what legislative vehicle the White House plans to use, or whether Congress will take up the framework in its current form.
The plan marks a rhetorical shift from familiar Republican healthcare fights focused on repealing the Affordable Care Act. Instead, it centers on consumer costs and includes a push for Most Favored Nation-style drug pricing, alongside measures targeting insurers, pharmacy benefit managers, and hospital pricing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze